Antimicrobial Glycopeptides: Synthesis and Antibacterial Activity of N-linked and O-linked Smaller Chain Glycopeptides

Abstract

Our objective is to synthesize the smaller chain N-linked and O-linked glycopeptides using sugars belong to mono, di and polysaccharides, with the efforts mainly directed towards the identification of antibacterial compounds. 7 glycopeptides, viz., Arg-Asn-Mannose, Arg-Asn-Lactose, His-Asn-Mannose, His-Asn-Lactose (N-glycopeptides), Arg-Ser-Lactose, Arg-Thr-Lactose, Arg-Thr-Starch (O-glycopeptides) were prepared by dicyclohexyl carbodimide (DCC) coupling for amino acids using microwave oven (50W power; 15 min) and activated and coupled with respective sugar moieties using microwave oven at 120 W for 20–25 min. The column eluted compounds were tested for disc diffusion assay using 3 gram positive S. aureus, B. subtilis, S. caprae and 3 gram negative E. coli, P. aeruginosa and S. sonnei strains at different concentrations predicted by pH and inhibitory concentrations. One of the test glycopeptide, His-Asn-Lactose was found to be very effective against all the microbial strains tested and 3 other Test Compounds, viz., His-Asn-Mannose, Arg-Thr-Lactose and Arg-Thr-Starch are also proved to be effective against 2 gram positive and 2 gram negative strains tested. Maximum activity was observed at a concentration of 450 μg/ml (747.51 µM) for the N-glycopeptide His-Asn-Lactose with the corresponding zonal inhibition diameters (15 mm; 19 mm; 14 mm; 18 mm; 16 mm; 17 mm) against S. aureus, B. subtilis, S. caprae, E. coli, P. aeruginosa, S. sonnei. This is the first evidence based report that our N-glycopeptide, His-Asn-Lactose tested, has shown antibacterial action against both gram positive and gram negative strains. Further in vivo testing and clinical studies will make sure to position our potent small chain N-glycopeptide in the arsenal of new broad spectrum anti-gram positive and negative agent.

Key words

antibacterial drugs - drug research - infectious diseases

• References

• 1 Talbot P, Shur BD, Myles DG. Cell adhesion and fertilization: Steps in oocyte transport, spermzona pellucida interactions, and sperm egg fusion. Biology of Reproduction 2003; 68: 1-9
• 2 Bertozzi CR, Kiessling LL. Chemical glycobiology. Science 2001; 291: 2357-2364
• 3 Biavasco F, Vignaroli C, Lupidi R et al. In-vitro antibacterial activity of LY 333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997; 41: 2165-2172
• 4 Hoffmann R, Bulet P, Urge L et al. Range of activity and metabolic stability of Synthetic antibacterial glycopeptides from insects. Biochim Biophys Acta 1999; 1426: 459-467
• 5 Goldstein BP, Candiani G, Arain TM et al. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1995; 39: 1580-1588
• 6 Cooper RD, Snyder NJ, Zweifel MJ et al. Reductive alkylation of glycopeptide antibiotics: Synthesis and antibacterial activity. J Antibiot (Tokyo) 1996; 49: 575-581
• 7 Grappel SF, Giovenella AJ, Philips L et al. Antimicrobial activity of aridicins, novel glycopeptide antibiotics with high and prolonged levels in blood. Antimicrob Agents Chemother 1985; 28: 660-662
• 8 Jorgensen JH, Redding JS, Maher LA. Antibacterial activity of the new glycopeptide antibiotic SKF 104662. Antimicrob Agents Chemother 1989; 33: 560-561
• 9 Shao C, Zhou W, Zhang S et al. Synthesis and antibacterial activity of N₄-mono alkyl derivatives of novel glycopeptide LYV07ww01. Biorg Med Chem Lett 2011; 21: 6732-6738
• 10 Arimoto H, Nishimura K, Hayakawa I et al. Multi-valent polymer of vancomycin: enhanced antibacterial activity against VRE. Chem Commun 1999; 1361-1362
• 11 Haiyin HE, Williamson RT, Shen BO et al. Mannopeptimycins, Novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J Am Chem Soc 2002; 124: 9729-9736
• 12 Candiani G, Abbondi M, Borgonovi M et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semisynthetic glycopeptide antibiotic. Journal of Antimicrobial Chemotherapy 1999; 44: 179-192
• 13 Nagarajan K, Singh S, Taleuzzaman M et al. Assessment of antioxidant potency of small chain glycopeptides using DPPH free radical scavenging assay. Journal of Pharmacy and Nutrition Sciences 2012; 2: 178-190
• 14 Bauer AW, Kirby WMM, Sherris JC et al. Antibiotic susceptibility testing by standardised single disk method. Am J Clin Pathol 1996; 45: 493-496
• 15 Hossain SM, Easmin S, Islam SM et al. Novel thiocyanato complexes with potent cytotoxic and antimicrobial properties. J Pharm Pharmacol 2004; 56: 1519-1520
• 16 Greenwood D. Antimicrobial chemotherapy. New York: Oxford Univ. Press; 2000: 36
• 17 Reiner R. Detection of antibiotic activity. In: Antibiotics an introduction. Switzerland: Roche Scientific Services; 1982: 21-25
• 18 Cappuccino JG, Sherman N. Microbiology – A Laboratory Manual. 4^th ed. California: The Benjamin Cummings Publishing Co. Inc; 1996: 21-23
• 19 Kobayashi K, Pillai SK. Applied Statistics in Toxicology and Pharmacology. New Delhi: Oxford and IBH Publishing Co. Pvt. Ltd; 2003: 19
• 20 Chanda S, Parekh J. In-vitro antimicrobial activity of some Indian folklore medicinal plants. J Cell Tissue Res 2006; 6: 577-580
• 21 Lin J, Opuku AR, Geheeb-keller M et al. Preliminary Screening of some traditional zulu medicinal plants for anti-inflammatory and anti-microbial activities. J Ethnopharmacol 1999; 68: 267-274
• 22 Pootoolal J, Thomas MG, Marshall CG et al. Assembling the glycopeptide antibiotic scaffold: The biosynthesis of A47394 from Streptomyces toyocaensis NRRL 15009. Proc Natl Acad Sci 2002; 99: 8962-8967
• 23 Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Biorg Med Chem Lett 2003; 13: 4165-4168
• 24 Cirioni O, Giacometti A, Ghiselli R et al. Propylactic efficacy of topical temporin A and RNA III-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to Staphylococci with intermediate resistance to glycopeptides. Circulation 2003; 108: 767-771
• 25 Bambeke FV. Glycopeptides and glycodepsipeptides in clinical development: A comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Current Opinion in Investigational Drugs 2006; 7: 740-749
• 26 Kahne D, Leimkuhler C, Lu W et al. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 2005; 105: 425-448
• 27 Ge M, Chen Z, Onishi HR et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 1999; 284: 507-511
• 28 Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 2005; 49: 1127-1134
• 29 Ruzin A, Singh G, Severin A et al. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram positive bacteria. Antimicrob Agents Chemother 2004; 48: 728-738